arrow
M

Marcin Kowanetz

roche holding
H指数:57
被引数:3.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

FURVENT, Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)
2024-04-050
PRE
Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer
2022-09-090
OAAI
BDC-2034: DISCOVERY OF A CEA-TARGETING IMMUNE-STIMULATING ANTIBODY CONJUGATE (ISAC) FOR SOLID TUMORS
2021-11-108
OA
PD-L1-TARGETED ISAC COMBINES MYELOID CELL ACTIVATION, IMMUNE-CHECKPOINT INHIBITION AND ADCP TO IMPROVE ANTI-TUMOR EFFICACY OVER ANTI-PD-L1 ANTIBODIES IN PRECLINICAL MODELS
2021-11-101
OA
Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors.
2021-07-013
PRE
Intratumoral CD103+CD8+T cells predict response to PD-L1 blockade

肿瘤内CD103 CD8 T细胞预测对PD-L1阻断的反应

2021-04-0791
OAAI
Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
2021-02-1513
PRE
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity

免疫刺激性抗体结合物引发强大的骨髓激活和持久的抗肿瘤免疫

2020-12-07120
OAAI
PHASE 1/2 STUDY OF NOVEL HER2-TARGETING, TLR7/8 IMMUNE-STIMULATING ANTIBODY CONJUGATE (ISAC) BDC-1001 WITH OR WITHOUT IMMUNE CHECKPOINT INHIBITOR IN PATIENTS WITH ADVANCED HER2-EXPRESSING SOLID TUMORS
2020-11-098
PREAI
Late-differentiated effector neoantigen-specific CD8+T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment

晚期分化效应新抗原特异性CD8 T细胞在对阿特珠单抗治疗有反应的非小细胞肺癌患者的外周血中富集

2019-09-1262
OAAI
Immune profiles in primary squamous cell carcinoma of the head and neck
2019-09-0156
OAAI